Shukla Ishav Y, Ebada Ali, Bever Nicholas, Traylor Jeffrey I, Wan Bingchun, Shah Darsh, Barnett Samuel L, Sun Matthew Z
Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA.
J Neurooncol. 2025 May 12. doi: 10.1007/s11060-025-05057-2.
PURPOSE: Predicting long-term outcomes after meningioma resection remains challenging. Ki-67/MIB-1 correlates with recurrence, yet its optimal cutoff is undefined. This study aims to establish a threshold that enhances risk stratification, improves recurrence prediction, and informs postoperative surveillance and adjuvant treatment strategies. METHODS: This is retrospective study of patients who underwent meningioma resection. Receiver operating characteristic (ROC) analysis determined the optimal MIB-1 cutoff for predicting recurrence and survival, providing area under the curve (AUC). This cutoff was then applied in Kaplan-Meier survival analyses and multivariable Cox regressions, controlling for age, sex, tumor diameter, tumor location, extent of resection, and adjuvant radiotherapy. RESULTS: A total of 404 patients were included. Median age was 55.0 years (range: 16-85) and 72.3% were female. The cohort primarily consisted of WHO Grade 1 (69.6%) and Grade 2 (30.0%) meningiomas. An optimal MIB-1 index cutoff of 4.1% was identified using ROC analysis with the Youden index for predicting recurrence (AUC = 0.661, p < 0.001) and survival (AUC = 0.717, p < 0.001). 241 patients (59.7%) had a MIB-1 < 4.1%, and 163 (40.3%) had a MIB-1 ≥ 4.1%. Patients with MIB-1 ≥ 4.1% had a higher risk of recurrence (HR = 2.9, p = 0.009) and mortality (HR = 2.8, p = 0.036). Patients with MIB-1 ≥ 4.1% demonstrated shorter recurrence-free survival (RFS) (119.0 vs. 129.0 months, p < 0.001) and overall survival (OS) (163.0 vs. 229.0 months, p < 0.001). CONCLUSION: We identified an optimal and actionable MIB-1 index cutoff of 4.1% which independently predicted recurrence, mortality, and shorter RFS and OS for patients undergoing meningioma resection. As the first study to establish and validate this threshold, our findings highlight its potential as an adjunct prognostic tool to refine risk stratification and guide postoperative management.
目的:预测脑膜瘤切除术后的长期预后仍然具有挑战性。Ki-67/MIB-1与复发相关,但其最佳临界值尚未明确。本研究旨在确定一个阈值,以加强风险分层、改善复发预测,并为术后监测和辅助治疗策略提供依据。 方法:这是一项对接受脑膜瘤切除术患者的回顾性研究。通过受试者操作特征(ROC)分析确定预测复发和生存的最佳MIB-1临界值,得出曲线下面积(AUC)。然后将该临界值应用于Kaplan-Meier生存分析和多变量Cox回归分析,同时控制年龄、性别、肿瘤直径、肿瘤位置、切除范围和辅助放疗等因素。 结果:共纳入404例患者。中位年龄为55.0岁(范围:16 - 85岁),女性占72.3%。该队列主要由世界卫生组织(WHO)1级(69.6%)和2级(30.0%)脑膜瘤组成。使用ROC分析及约登指数确定预测复发(AUC = 0.661,p < 0.001)和生存(AUC = 0.717,p < 0.001)的最佳MIB-1指数临界值为4.1%。241例患者(59.7%)的MIB-1 < 4.1%,163例(40.3%)的MIB-1≥4.1%。MIB-1≥4.1%的患者复发风险更高(HR = 2.9,p = 0.009),死亡风险更高(HR = 2.8,p = 0.036)。MIB-1≥4.1%的患者无复发生存期(RFS)较短(119.0个月对129.0个月,p < 0.001),总生存期(OS)也较短(163.0个月对229.0个月,p < 0.001)。 结论:我们确定了一个最佳且可操作的MIB-1指数临界值为4.1%,该值可独立预测脑膜瘤切除术后患者的复发、死亡以及较短的RFS和OS。作为首个建立并验证该阈值的研究,我们的发现凸显了其作为辅助预后工具以优化风险分层和指导术后管理的潜力。
Cochrane Database Syst Rev. 2022-9-26
Cochrane Database Syst Rev. 2023-1-23
JAMA Oncol. 2025-4-3
J Neurosurg. 2023-3-1
J Neurooncol. 2023-1
Lancet Digit Health. 2022-12
Neuro Oncol. 2021-11-2